Want to see AU:AHE full AI Analyst Report?
AHE Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$7.65M
Enterprise ValueAU$17.93M
Total Cash (Recent Filing)AU$8.09M
Total Debt (Recent Filing)AU$180.92K
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding637,676,800
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$112.30M
Bulls Say, Bears Say
Bulls Say
Platform Business ModelMedAdvisor’s core pharmacy software and consumer medication app represent a platform business that can drive recurring engagement and stickiness across pharmacies and patients. Platform roles (prescription/refill workflows, adherence messaging) create durable customer touchpoints and potential for multi-year contracts or network effects.
Improving Free Cash FlowReported free cash flow growth of +18.49% signals the company has begun to improve cash generation relative to prior periods. If sustained, this trend can extend runway, reduce near-term financing dependence, and support reinvestment into product or customer retention initiatives despite current operating cash challenges.
Positive Return On EquityA positive return on equity, even when equity is depressed, suggests certain parts of the business generate returns efficiently. This indicates operational capabilities or margin potential in core offerings that, with balance sheet repair and scale restoration, could translate into improved long-term profitability.
Bears Say
Sharp Revenue DeclineA near 40% year decline in revenue is structurally damaging: it reduces scale, weakens pricing leverage, and makes fixed-cost absorption harder. Sustained top-line contraction impairs the ability to invest in sales, R&D, and product improvements, threatening long-term competitiveness and recovery prospects.
Deep Negative ProfitabilityNet margin near -96% and negative EBIT/EBITDA indicate persistent operating losses and structural cost issues. Such deep unprofitability erodes cash reserves, increases reliance on external funding, and undermines the company’s ability to scale or sustain R&D and customer acquisition over the medium term without significant remediation.
Stressed Balance Sheet / Negative EquityNegative shareholder equity and an extreme debt-to-equity metric point to solvency and refinancing risk. This structural weakness limits capital access, could impose restrictive financing terms, and may force dilutive financing or asset sales to repair the balance sheet, hindering long-term strategic choices.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.01 and its highest was AU$0.09 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$7.65M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Aug 27, 2026 which is in 56 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Feb 26, 2026. The company reported AU$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.011.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 637,676,800 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of AU$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AHE Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$20.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
-209.68%
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.
Options Prices
Currently, No data available
---